Important message: Due to recent site outage we are still restoring full functionality to Authorea powered sites. Please bear with us until full functionality is restored

loading page

The Impact of Concomitant Proton Pump Inhibitors Therapy on Clinical Outcome of Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis
  • +3
  • cao xing,
  • wang yafei,
  • huang wei,
  • li panyun,
  • guo chongjie,
  • li yuhui
cao xing
The Central Hospital of Wuhan

Corresponding Author:[email protected]

Author Profile
wang yafei
The Central Hospital of Wuhan
Author Profile
huang wei
The Central Hospital of Wuhan
Author Profile
li panyun
The Central Hospital of Wuhan
Author Profile
guo chongjie
The Central Hospital of Wuhan
Author Profile
li yuhui
The Central Hospital of Wuhan
Author Profile

Abstract

Background: In patients with advanced cancer receiving immune checkpoint inhibitors (ICIs) therapy, there are conflict perspectives about the influence of concomitant use of proton pump inhibitors (PPIs). We are aimed at exploring the influence of concomitant PPIs exposure on clinical outcome among cancer patients receiving ICIs treatment. Methods: We searched relevant literatures in PubMed, EMBASE, and the Cochrane Library without language restrictions. We extracted the data from selected studies and calculated the pooled hazard ratios (HRs) with 95% confidence intervals (CIs) through professional software for overall survival (OS) and progression free survival (PFS) among cancer patients undergoing ICIs therapy exposed to PPIs. Results: Fourteen studies including 6716 advanced cancer patients receiving ICIs treatment were appropriate for analysis judging by pre-set inclusion and exclusion criteria. The result indicated that concomitant PPIs exposure was significantly related to shorter OS (HR 1.388; 95%CI:1.278-1.498, P<0.001) and PFS (HR 1.285;95%CI:1.193-1.384, P<0.001) among multiple cancer patients receiving ICIs therapy. Conclusions: Our meta-analysis showed that concomitant PPIs exposure had adverse impact on clinical outcome among patients receiving ICIs therapy. Clinical oncologists must be cautious of PPIs delivery during ICIs treatment.